At present, there are only two ways to detect Intracranial bleed, CT Scan or neurological examination by a paramedic staff. CT is not available everywhere, and it takes at least 30-40 minutes from the time the patient arrives at the time to when the result is obtained. A neurological examination is subjective and is a poor indicator of injury especially in the case of mildly symptomatic and asymptomatic patients. To overcome this, we are developing an NIR spectroscopy based device that will scan the patient's head and indicate the presence of bleed along with lobe location within 2 minutes. Our device is designed to be operated by a semi-skilled staff in three simple steps because of the graphical interface, robustness for field operation due to opto-mechanical assembly design and affordability in terms of per-test cost due to disposable design. These three characteristics make it an ideal device to screen the masses in order to detect haemorrhages at an early stage when the patient might be otherwise missed.
Technology Features, Specifications and Advantages
This technology is an on the spot assessment tool for instantaneous detection of intracranial bleed. It is fast and just takes 2 minutes to scan the whole head. It is handy, so it can be carried around easily, especially to the site of injury. It's fully computerized, so anybody with only 10 minutes of training can operate it irrespective of the literacy level. It is non-invasive since it is based on NIR spectroscopy and hence can scan the patient's head multiple times without causing any harm. Three versions of CereboTM; would be available to the potential market - CereboTM; Value, CereboTM; Plus, CereboTM; Cloud.; Value is the no-frills option that facilitates testing of one person at a time. CereboTM; Plus is a testing and monitoring device. It keeps multiple records per patient for 100 patients. CereboTM; Cloud is the cloud version of CereboTM and maintains all the records on the cloud.
CT Scan is the gold standard for intracranial bleed detection, however, it is limited for mass screening because it is non-portable, exposes a person to high energy radiation, and needs a radiologist to interpret the result. In the absence of CT scans, a neurological examination, like the Glasgow Coma Scale, is the most common examination conducted by a paramedic staff in present times to screen the patients for any neuro-trauma condition. The challenge with this examination is that it is a subjective examination, needs trained-staff to conduct it, and is a poor indicator of haemorrhage in asymptomatic or mildly symptomatic conditions. Hence, a lot of patients become vulnerable to late diagnosis or misdiagnosis.
On the other hand, CereboTM does not use any ionizing radiation and is therefore not harmful. It is portable and does not require any special skills to operate the device and hence can be operated by a common man in a rural village or small town with minimal training.
50 million people become victims of Traumatic brain injury every year in the world. Around 60% of them never return to normal life not because of a lack of treatment but because of delays in detection. TBI patients do not prefer to go to a CT centre when they are mildly symptomatic or asymptomatic and this leads to irreparable brain damage by the time clinical symptoms arise and the patient goes to the hospital. Neurological examination like GCS is also a poor indicator of haemorrhages when the patient is mildly symptomatic or asymptomatic. And that is why TBI is associated with very high mortality and disability rates. With CerebroTM, we would be able to detect haemorrhages at an early stage and hence increase not only the chances of survival of patients but also positive outcomes post-surgery.
We present this project as the most effective solution to the problem.